When, despite the use of dopaminergic drugs, patients develop motor fluctuations and/or dyskinesias, treatment with Monoamine oxidase B (MAO-B) inhibitors (safinamide, rasagiline, or selegiline), Catechol-O-Methyl-Transferase (COMT) inhibitors (opicapone, entacapone, or tolcapone), subcutaneous apomorphine, amantadine, and/or zonisamide is recommended [2]. This evidence concerns the gene MAOB and Dyskinesia.